These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22144483)

  • 21. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
    Torres JF; Lyerly DM; Hill JE; Monath TP
    Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of Clostridium difficile toxin A using antibody combinations.
    Demarest SJ; Hariharan M; Elia M; Salbato J; Jin P; Bird C; Short JM; Kimmel BE; Dudley M; Woodnutt G; Hansen G
    MAbs; 2010; 2(2):190-8. PubMed ID: 20150758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
    Warny M; Vaerman JP; Avesani V; Delmée M
    Infect Immun; 1994 Feb; 62(2):384-9. PubMed ID: 8300199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models.
    Vitucci JC; Pulse M; Tabor-Simecka L; Simecka J
    BMC Microbiol; 2020 Feb; 20(1):27. PubMed ID: 32024477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
    Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
    Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active and passive immunization against Clostridium difficile diarrhea and colitis.
    Giannasca PJ; Warny M
    Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.
    Lyerly DM; Bostwick EF; Binion SB; Wilkins TD
    Infect Immun; 1991 Jun; 59(6):2215-8. PubMed ID: 2037383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.
    Amadou Amani S; Lang GA; Ballard JD; Lang ML
    Infect Immun; 2021 Sep; 89(10):e0027421. PubMed ID: 34097471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
    Ward SJ; Douce G; Figueiredo D; Dougan G; Wren BW
    Infect Immun; 1999 May; 67(5):2145-52. PubMed ID: 10225867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.
    Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
    Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
    [No Abstract]   [Full Text] [Related]  

  • 40. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.
    Gardiner DF; Rosenberg T; Zaharatos J; Franco D; Ho DD
    Vaccine; 2009 Jun; 27(27):3598-604. PubMed ID: 19464540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.